Big Pharma in the Cancer Spotlight?

Move over biotech -- drug giants like Bristol-Myers Squibb and Pfizer could steal the show at this year's premier oncology confab

Biotech investors are unusually quiet for this time of year. Over the past few years the biotech sector has dominated the news coming out of the annual American Society of Clinical Oncology (ASCO) meeting, the world's most important cancer conference. And their stocks typically start moving a week or two ahead of the meeting in anticipation of those headlines.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.